Results—2
| . | IFN + PUVA . | IFN + Acitretin . |
|---|---|---|
| IFN dose (MU) | ||
| All patients | ||
| Mean | 569 | 609 |
| Range | 99-1,287 | 36-1,287 |
| Patients with CR | 603 | 507 |
| Patients with no CR | 487 | 673 |
| Duration of IFN treatment (wk) | ||
| All patients (mean) | 23.9 | 25.5 |
| Patients with CR | 24.6 | 22.5 |
| Patients with no CR | 22.1 | 27.3 |
| Acitretin dose (mg) | ||
| All patients | ||
| Mean | 6,556 | |
| Range | 375-16,660 | |
| Patients with CR | 5,962 | |
| Patients with no CR | 6,927 | |
| PUVA dose ( J/cm2) | ||
| All patients | ||
| Mean | 139 | |
| Range | 11.2-406.5 | |
| Patients with CR | 158.6 | |
| Patients with no CR | 94.8 | |
| No. of PUVA treatments | ||
| All patients (mean) | 58.5 | |
| Patients with CR | 61.2 | |
| Patients with no CR | 51.5 |
| . | IFN + PUVA . | IFN + Acitretin . |
|---|---|---|
| IFN dose (MU) | ||
| All patients | ||
| Mean | 569 | 609 |
| Range | 99-1,287 | 36-1,287 |
| Patients with CR | 603 | 507 |
| Patients with no CR | 487 | 673 |
| Duration of IFN treatment (wk) | ||
| All patients (mean) | 23.9 | 25.5 |
| Patients with CR | 24.6 | 22.5 |
| Patients with no CR | 22.1 | 27.3 |
| Acitretin dose (mg) | ||
| All patients | ||
| Mean | 6,556 | |
| Range | 375-16,660 | |
| Patients with CR | 5,962 | |
| Patients with no CR | 6,927 | |
| PUVA dose ( J/cm2) | ||
| All patients | ||
| Mean | 139 | |
| Range | 11.2-406.5 | |
| Patients with CR | 158.6 | |
| Patients with no CR | 94.8 | |
| No. of PUVA treatments | ||
| All patients (mean) | 58.5 | |
| Patients with CR | 61.2 | |
| Patients with no CR | 51.5 |